2 results
Approved WMOWill not start
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.
Approved WMORecruiting
The primary objectives of this study are:• To determine the safety and tolerability of EP-104IAR• To determine the pharmacokinetic (PK) profile of EP-104IARA secondary/exploratory objective is:• To evaluate the efficacy of EP-104IAR on eosinophilic…